We assessed the relationships among adult height, coronary artery calcium (CAC) score, incident atherosclerotic cardiovascular disease (ASCVD) events, and atrial fibrillation (AFib) in a multiethnic cohort. We used race/ethnicityspecific height (dichotomized by median value and in quartiles) as the predictor variable within the 4 racial/ethnic groups in the Multi-Ethnic Study of Atherosclerosis (n = 6,814). After a mean of 10.2 years of follow-up (2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012), 556 ASCVD events (8.2%) and 539 AFib events (7.9%) occurred. Adult height was not associated with prevalent CAC score (ln(CAC + 1) or categories). Tall stature (i.e., race/ethnicity-specific height ≥median) had a significant but opposite association with future ASCVD and AFib (hazard ratios were 0.72 (95% confidence interval: 0.56, 0.92) and 1.38 (95% confidence interval: 1.07, 1.79), respectively). We observed a gradient-response but opposite association between quartiles of race/ethnicity-specific height and ASCVD/AFib events in our multivariable models. A formal test of interaction between race/ethnicity-specific height and sex was not significant in the ASCVD model (P = 0.78) but was significant in the AFib model (P = 0.03). Tall stature was associated (in a gradient-response fashion) with reduced risk of ASCVD events and increased risk of AFib. Adult height may signal interactions between genetic and environmental factors and may provide risk information independent of current traditional risk factors and CAC score. adult height; atherosclerotic cardiovascular disease; atrial fibrillation; cardiovascular disease; coronary artery calcium score
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We assessed the relationships among adult height, coronary artery calcium (CAC) score, incident atherosclerotic cardiovascular disease (ASCVD) events, and atrial fibrillation (AFib) in a multiethnic cohort. We used race/ethnicityspecific height (dichotomized by median value and in quartiles) as the predictor variable within the 4 racial/ethnic groups in the Multi-Ethnic Study of Atherosclerosis (n = 6,814). After a mean of 10.2 years of follow-up (2000-2012), 556 ASCVD events (8.2%) and 539 AFib events (7.9%) occurred. Adult height was not associated with prevalent CAC score (ln(CAC + 1) or categories). Tall stature (i.e., race/ethnicity-specific height ≥median) had a significant but opposite association with future ASCVD and AFib (hazard ratios were 0.72 (95% confidence interval: 0.56, 0.92) and 1.38 (95% confidence interval: 1.07, 1.79), respectively). We observed a gradient-response but opposite association between quartiles of race/ethnicity-specific height and ASCVD/AFib events in our multivariable models. A formal test of interaction between race/ethnicity-specific height and sex was not significant in the ASCVD model (P = 0.78) but was significant in the AFib model (P = 0.03). Tall stature was associated (in a gradient-response fashion) with reduced risk of ASCVD events and increased risk of AFib. Adult height may signal interactions between genetic and environmental factors and may provide risk information independent of current traditional risk factors and CAC score. adult height; atherosclerotic cardiovascular disease; atrial fibrillation; cardiovascular disease; coronary artery calcium score Abbreviations: ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CI, confidence interval; CT, computed tomography; CVD, cardiovascular disease; HR, hazard ratio; IQR, interquartile range; MESA, Multi-Ethnic Study of Atherosclerosis; NRI, net reclassification improvement; PCE, Pooled Cohort Equations.
Current epidemiologic data regarding the association between adult height and cardiovascular disease (CVD) are equivocal (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . While some reports suggest an association between short stature and CVD risk factors (1, 2) and subclinical (3) and clinical (4) CVD outcomes, others do not, especially in nonwhite populations (5) (6) (7) (8) (9) (10) . More recently, an association was reported between genetically determined shorter height and an increased risk of coronary artery disease in whites. The authors postulated that most of the relationship is probably determined by shared biological processes that determine achieved height and atherogenesis (11) .
Short stature has been inversely associated with atrial fibrillation, the commonest form of arrhythmia in adults. While the limited data on the inverse association between short stature and atrial fibrillation appear uniform, study participants have been mostly whites (12) (13) (14) (15) (16) . A genetic study which included African Americans even suggested that European ancestry is a risk factor for atrial fibrillation in African Americans (17) .
In addition to the fact that most of these studies were crosssectional, the lack of racial/ethnic diversity in the cohorts limits the generalizability of their findings. Achieved adult height is not modifiable, and it varies by race/ethnicity and sex. Therefore, although establishing an association between adult height and CVD would not be useful for reducing risk, such an association might suggest more aggressive treatment or control of modifiable risk factors in individuals based on their height, an approach which may further decrease the prevalence of CVD.
We assessed associations among adult height, prevalent coronary artery calcium (CAC) score, 10 years of adjudicated incident atherosclerotic cardiovascular disease (ASCVD), and atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis (MESA), an ongoing prospective study funded by the National Heart, Lung, and Blood Institute.
METHODS

Study population and data collection
Information on the design of the MESA study has been published previously (18) . In brief, MESA is a prospective cohort study begun in July 2000 to investigate the prevalence, correlates, and progression of subclinical CVD in persons without known CVD at baseline. Thus, adults with known ASCVD or atrial fibrillation were excluded from this study at baseline. The cohort included 6,814 women and men aged 45-84 years at baseline, recruited from 6 US communities (Baltimore, Maryland; Chicago, Illinois; Forsyth County, North Carolina; Los Angeles County, California; northern Manhattan, New York, New York; and St. Paul, Minnesota). MESA participants were 38% white (n = 2,624), 28% African-American (n = 1,895), 22% Hispanic (n = 1,492), and 12% Chinese-American (n = 803). Persons with a history of physician-diagnosed myocardial infarction, angina, heart failure, stroke, or transient ischemic attack or who had undergone an invasive procedure for CVD (coronary artery bypass graft, angioplasty, valve replacement, pacemaker placement, or other vascular surgery) were excluded from enrollment. This study was approved by the institutional review boards at each study site, and written informed consent was obtained from all participants.
Demographic, medical history, anthropometric, and laboratory data for this study were obtained at the first MESA examination (July 2000-August 2002). Current smoking was defined as having smoked a cigarette in the last 30 days. Diabetes mellitus was defined as fasting glucose concentration greater than or equal to 126 mg/dL or the use of hypoglycemic medication. Use of antihypertensive and other medications was based on review of prescribed medication containers. Resting blood pressure was measured 3 times with the participant seated, and the average of the second and third readings was recorded. Hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or use of medication prescribed for hypertension. Body mass index was calculated as weight (kg)/height (m) 2 . Total cholesterol and high-density lipoprotein cholesterol were measured from blood samples obtained after a 12-hour fast. Low-density lipoprotein cholesterol was estimated by means of the Friedewald equation (19) .
Height measurement
Participants' height was measured using a stadiometer (Seca Accu-Hite measuring device with level bubble; Seca GmbH & Co. KG, Hamburg, Germany) while the participant stood erect on a level floor with heels against a wall at a 90-degree angle to the floor and feet or knees together. The stadiometer was then mounted perpendicular to the floor. With the participant's head in the Frankfort horizontal plane, the headboard was placed over the crown of the head with the headboard lightly touching the scalp. Participants were then asked to step out from under the headboard. The height of the participants was recorded to the nearest 0.1 cm.
Adult height varies by race/ethnicity and sex. Since the strength of MESA is its multiethnic cohort, race/ethnicity-specific height (dichotomized by the median value and in quartiles) was used as the predictor variable in our analyses. Sex was adjusted for in each model, including the univariable model. Each analysis was also stratified by sex for assessment of whether an inherent sex imbalance accounted for our findings, despite the inclusion of sex in all models.
CAC score
Details of the MESA computed tomography (CT) scanning and interpretation methods have been reported previously (20) . CAC was assessed at scanning centers by means of chest CT with either a cardiac-gated electron-beam CT scanner (Chicago, Los Angeles, and New York field centers) or a multidetector CT system (Baltimore, Forsyth County, and St. Paul field centers). Certified technologists scanned all participants twice over phantoms of known physical calcium concentration. A radiologist or cardiologist read all CT scans at a central reading center (Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California). We used the mean Agatston score for the 2 scans in all analyses (21) . Intraobserver and interobserver agreement were excellent (κ = 0.93 and κ = 0.90, respectively). Only baseline CAC was used in the present analysis.
Event ascertainment
A detailed description of the event ascertainment procedures and adjudication process used in MESA has been published previously (22) . Briefly, every 9-12 months since the baseline examination, MESA participants (or, when necessary, their proxies) have been contacted to inquire about any hospital admissions, CVD diagnoses, or deaths that may have occurred. Hospital and other documentation of possible CVD events and deaths has subsequently been obtained. These documentations are sent to at least 2 members of the MESA Morbidity and Mortality Committee for adjudication using a standard protocol. This committee includes cardiologists, physician-epidemiologists, and neurologists. If any events are not uniformly adjudicated by at least 2 Committee members, they are discussed and voted on by the entire Committee during its monthly meetings. For the purposes of this study, we defined incident ASCVD as adjudicated myocardial infarction, coronary heart disease death, and fatal and nonfatal stroke, as described in the MESA protocol (www. mesa-nhlbi.org).
The atrial fibrillation variable used in this study was a combined one consisting of 1) cases adjudicated by the MESA adjudication committee and 2) for participants aged ≥65 years enrolled in fee-for-service Medicare programs, Medicare claims data. Inpatient cases of atrial fibrillation were defined by International Classification of Diseases, Ninth Revision, code 427.31 or 427.32. Figure 1 presents a flow chart of the MESA study and the events adjudicated during a mean of 10.2 years of follow-up.
Statistical analysis
The demographic characteristics of participants are reported by race/ethnicity-specific height (less than the median or greater than or equal to the median) as mean values and standard deviations for continuous variables and as frequencies or percentages for categorical variables.
Associations between CAC and race/ethnicity-specific height (<median vs. ≥median) were assessed using linear regression modeling, where CAC score was introduced into the models as a log-transformed continuous variable (ln(CAC + 1)), and logistic regression modeling, where CAC was dichotomized as zero versus more than zero, <100 versus ≥100, and <300 versus ≥300. We adjusted for covariates such as age, sex, race/ethnicity, weight, systolic and diastolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, diabetes mellitus, cigarette smoking, use of blood pressure medication, and baseline statin use. Results of each analysis were stratified by sex.
Event-free survival curves of participants below and at or above the race/ethnicity-specific median height for incident ASCVD events were assessed using the survival function test, adjusting for age and sex. Cox proportional hazards analysis was also used to assess the association between race/ethnicityspecific height (<median vs. ≥median) and incident ASCVD events via 2 models. Model 1 adjusted for age and sex, and model 2 adjusted for model 1 variables plus race/ethnicity, weight, systolic and diastolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, diabetes mellitus, cigarette smoking, use of blood pressure medication, and statin use. A gradient-response association between adult height and ASCVD events was assessed using quartiles of race/ethnicity-specific height in our full multivariable models (with the lowest quartile (quartile 1) used as the reference category). Ten-year ASCVD risk was calculated for each participant (including those with type 2 diabetes mellitus) using the Pooled Cohort Equations (PCE) (23) . The PCE include race/ethnicity-specific risk estimates for blacks and whites only. Risk estimates for Hispanic and Chinese-American participants were calculated using the PCE for whites, as suggested in the new guidelines (23). Harrell's C statistics were assessed for our full multivariable model, the full model plus race/ethnicity-specific height (binary), the PCE, and the PCE plus race/ethnicity-specific height (binary) for incident ASCVD. The improvement in discrimination afforded by race/ethnicity-specific height over and beyond the PCE was also assessed using Harrell's C statistic and net reclassification improvement (NRI) analysis (using the clinically recognized dichotomy of PCE <7.5% and PCE ≥7.5%).
The above Kaplan-Meier and Cox proportional hazards analyses were repeated with incident atrial fibrillation as the outcome of interest. The Harrell's C statistics for our full multivariable model and the full model plus race/ethnicity-specific height (binary) were assessed for incident atrial fibrillation. Harrell's C statistic for the atrial fibrillation risk score (24) and the improvement afforded by adding race/ethnicity-specific height (binary) were not assessed, since body mass index is a component of the atrial fibrillation risk score (24) . All statistical analyses were performed using SAS software (version 9.2; SAS Institute, Inc., Cary, North Carolina).
RESULTS
The median heights of white, Chinese-American, AfricanAmerican, and Hispanic participants were 168.5 (interquartile range (IQR), 161.6-176.2) cm, 161.5 (IQR, 155.0-168.0) cm, 167.9 (IQR, 161.0-175.6) cm, and 161.0 (IQR, 154.0-169.1) cm, respectively. After a mean of 10.2 years of follow-up, 556 of 6,814 participants (8.2%) had an adjudicated ASCVD event, 247 (3.6%) had an adjudicated myocardial infarction, 233 (3.4%) had an adjudicated stroke, and 539 (7.9%) had atrial fibrillation. Participants with race/ethnicity-specific height less than the median (short stature) were mostly female and older and had worse lipid profiles and systolic blood pressure levels, and hence were more likely to be taking antihypertensive or statin medications compared with those whose race/ ethnicity-specific height was at the median value or higher (tall stature) ( Table 1 ; also see Web Table 1 , available at https:// academic.oup.com/aje).
Adult height and prevalent CAC
Race/ethnicity-specific height was not associated with prevalent CAC in linear regression models when CAC score was introduced into models as ln(CAC + 1) (model 1: β = 0.063 (standard error, 0.07), P = 0.39; model 2: β = 0.009 (standard error, 0.07), P = 0.90). Race/ethnicity-specific height was not associated with ln(CAC + 1) in either men or women when the linear regression model stratified results by sex. As Table 2 and Figure 1 show, race/ethnicity-specific height was not significantly associated with CAC categories. No associations between race/ethnicity-specific height and CAC categories were found in men or women when results were stratified by sex.
Adult height and incident ASCVD
Participants with tall stature had significantly less risk of an ASCVD (approximately 25% less) than those with short stature (Figures 2 and 3A, Table 3 ). With the lowest race/ethnicityspecific height quartile as the reference group (quartile 1), a gradient-response association was observed between adult height and future ASCVD events Race/ethnicity-specific height (binary) was also an independent predictor of ASCVD events when ln(CAC + 1) was forced into the full model (HR = 0.72, 95% CI: −0.56, 0.91; P = 0.007). Similar point estimates for reduction of risk were seen for future myocardial infarction and stroke, even though the 95% confidence interval crossed 1 due to less power in these analyses ( Table 3) .
The C statistic for our full multivariable model (model 2) for ASCVD was 0.725. The addition of race/ethnicity-specific height (binary variable) or height as a continuous variable did not improve discrimination when added to the full model (model 2) (C statistic = 0.727, P = 0.52). The PCE (ASCVD risk score) produced a C statistic of 0.724 for ASCVD events; adding race/ethnicity-specific height (binary) or height as a continuous variable did not improve discrimination (C statistic = 0.725, P = 0.61). However, when the C statistics of the PCE were stratified by race/ethnicity-specific median height, the C statistic was significantly higher in participants with short stature than in those with tall stature (0.733 vs. 0.714; P = 0.02 for difference) (Figure 4 ). The addition of height to the ASCVD risk score categories (PCE <7.5% and PCE ≥7.5%) produced an event NRI of 0.031 (95% CI 
Adult height and atrial fibrillation
Participants with tall stature also had a significantly higher risk of incident atrial fibrillation compared with those with short stature (Figures 2 and 3B, Table 3 ). With the lowest race/ ethnicity-specific height quartile (quartile 1) used as the reference group, a gradient-response association was also observed between adult height and atrial fibrillation (quartile 2: HR = 1.18 (95% CI: 0.90, 1.55); quartile 3: HR = 1.54 (95% CI: 1.12, 2.12); quartile 4: HR = 1.67 (95% CI: 1.16, 2.42)) in our full multivariable model. A formal test for interaction between race/ethnicity-specific height and sex was significant in our Cox models for incident atrial fibrillation (P = 0.03). When analyses were stratified by sex, tall stature was associated with increased risk of future atrial fibrillation in women (model 1: HR = 2.06 (95% CI: 1.52, 2.80); model 2: HR = 1.79 (95% CI: 1.30, 2.46)) but not in men (model 1: HR = 1.09 (95% CI: 0.78, 1.51); model 2: HR = 1.00 (95% CI: 0.70, 1.40)). Race/ ethnicity-specific height (binary) was an independent predictor of atrial fibrillation when ln(CAC + 1) was forced into the full model (HR = 1.42, 95% CI: 1.10, 1.84; P = 0.008). The C statistics for our full model and the full model plus race/ethnicityspecific height (binary) were 0.728 and 0.731, respectively (P for difference not significant).
DISCUSSION
Our goal in this study was to assess the predictive value of adult height for incident ASCVD and atrial fibrillation in MESA, the most ethnically diverse prospective cohort study in the United States. We found no association between adult height and CAC. Tall stature was associated with an increased risk of future atrial fibrillation but a reduced risk of future ASCVD events. Although these divergent associations between adult height and ASCVD and atrial fibrillation have been observed before (2, 4, 5, 12, 13) , to our knowledge this is the first study to have demonstrated these associations in a multiethnic cohort. In addition, the ASCVD risk estimator (PCE) has a significantly lower discriminative ability for future ASCVD events in persons with tall stature compared with shorter individuals. Our findings are also consistent with secular trends in adult height, ASCVD, and atrial fibrillation from the 1960s to the present, especially in developed countries Abbreviations: CAC, coronary artery calcium; CI, confidence interval; OR, odds ratio.
a Stratified by sex. Results were adjusted for age and sex. b Stratified by sex. Results were adjusted for age, sex, race/ethnicity, weight, systolic and diastolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, diabetes mellitus, cigarette smoking, use of blood pressure medication, and statin use. Atherosclerotic plaques, a measure of vascular age, can be calcified or noncalcified. CAC score is a measure of calcified atherosclerotic plaque burden. CAC score is an independent predictor of both ASCVD events and atrial fibrillation (26) (27) (28) . In the present analysis, adult height was an independent predictor of both ASCVD events and atrial fibrillation, albeit in opposite directions. However, adult height was not associated with prevalent CAC in the present analysis. Associations of adult height with ASCVD and atrial fibrillation remained significant when prevalent CAC, as either a continuous variable (ln(CAC + 1)) or CAC categories, was forced into our full multivariable model. Adult height may provide information about an individual's future risk of CVD events over and beyond the present measures of vascular age, such as CAC.
Adult height results from a combination of genetic and environmental factors, especially during childhood (29) (30) (31) . The heritability of height is reported as between 0.60 and 0.95 (29) , and height is less heritable in women than in men (30, 31) . Thus, 60%-95% of the variance in height within a population can be accounted for by the variance of genes within that population. However, heritable traits are usually also affected by the environment. Unlike genetically specified traits such as numbers of fingers, heritable traits such as height result from interactions between genes and the environment, especially during childhood. Chronic diseases such as CVD result from an accumulation of insults (nutritional, diseases, stress, childhood socioeconomic factors, etc.) to the body that starts from birth/childhood. Thus, adult stature may be a signal of insults sustained by the cardiovascular system since birth/childhood, and may therefore be informative about predicting future clinical CVD. All of the advances made in the past several decades that have resulted in a better environment and therefore taller humans may have led to higher prevalence of a phenotype which is less susceptible to atherosclerosis but more susceptible to atrial fibrillation. The present study adds to the growing body of work suggesting that adult stature maybe a nonmodifiable CVD risk factor. Nonmodifiable risk factors are as important as modifiable risk factors for CVD risk assessment (23, 24, 32) . Nonmodifiable risk factors are included in CVD risk scores and help estimate the ultimate 10-year risk of future CVD. Thus, nonmodifiable risk factors help determine how aggressively modifiable risk factors should be treated or controlled in individuals. Our findings suggest that short stature may signal relatively higher risk for future ASCVD in an asymptomatic population-dwelling adult, and may warrant more aggressive control of modifiable ASCVD risk factors versus a taller individual with the same 10-year ASCVD risk score. Large atrial size is an independent predictor of future lone atrial fibrillation (33, 34) . Even though large atria are thought to be a result of atrial remodeling (35) , tall stature is also independently associated with larger atrial size (34) . Thus, large atria may be a nidus or substrate for future atrial fibrillation independent of the underlying cause (pathological or nonpathological). It is therefore plausible that for persons with large atria because of tall stature (nonpathological), risk-factor modification may not reduce risk of future atrial fibrillation.
Neither the Framingham risk score (24) nor the PCE (23) incorporate adult height. The PCE have suboptimal discriminative ability for ASCVD risk assessment in various populationbased cohorts (36) (37) (38) . In this study of the MESA cohort, adding adult height to the PCE did not improve discrimination for ASCVD events. However, the ASCVD risk score (PCE) had significantly higher discriminative ability for future ASCVD events among shorter persons versus taller persons in the MESA cohort (using Harrell's C statistic but not when NRI was used). Our study used only race/ethnicity-specific height (dichotomized at the median) as the predictor variable. It is plausible that the ASCVD risk score may have better discriminative ability for 10-year ASCVD events in persons with a certain stature. Replication of this finding is needed in other cohorts. Our study also had limitations. MESA is an observational study; thus, although our analyses adjusted for multiple covariates, our results may still have been due to residual confounding. Our null association between adult height and prevalent CAC may have been due to selection bias. MESA recruited healthy, community-dwelling adults by design. Therefore, it is possible that an association between height and prevalent CAC exists in the general population but was missed in our study due to selection bias. We used baseline data on medication use (e.g., antihypertensive agents and statins) in our models. Any changes in medication use during the follow-up period would not have been accounted for accurately in our models and may have affected our event rates and therefore our results. In addition to adjudicated events, the atrial fibrillation events used for this analysis included cases ascertained from inpatient Medicare claims data using International Classification of Diseases, Ninth Revision, codes. Although this strategy improved our event detection rate for incident atrial fibrillation, it may also have increased the possibility of misclassifying an atrial fibrillation event. However, this error seems unlikely, since inclusion of only adjudicated cases of atrial fibrillation in analyses produced similar results. Finally, the MESA cohort is not necessarily representative of the entire nation's population.
In conclusion, in the MESA cohort, race/ethnicity-specific height was independently associated with future ASCVD events and atrial fibrillation, albeit in opposite directions. Race/ethnicityspecific height was not associated with prevalent CAC. Adult height may be a signal of the interaction between genetic and environmental factors and may provide information on CVD risk independent of current traditional risk factors as well as CAC. Replication of our findings is needed in other nonwhite cohorts.
